Key result
Highest NIM-IL6 index quartile linked to ~45% lower all-cause mortality versus the lowest quartile.
Why the study?
A biomarker of vagal neuroimmunomodulation (NIM) was proposed to index cholinergic anti-inflammatory pathway functionality, but its association with all-cause mortality in general populations was unexplored.
Is a lower index of vagal neuroimmunomodulation associated with higher all-cause mortality in the general population?
Cohort (n=3,860)
Yes
Is a lower index of vagal neuroimmunomodulation associated with higher all-cause mortality in the general population?
Hazard Ratio: 0.55 (95% CI 0.41–0.73)
p-value: p=<0.0001
A novel index of vagal neuroimmunomodulation, combining heart rate variability and inflammatory markers, is significantly associated with all-cause mortality and may be useful for risk stratification.
NIM-ratio may index mortality risk in general populations; extends prior findings but remains hypothesis-generating without prospective validation.
In recent clinical practice, a biomarker of vagal neuroimmunomodulation (NIM), namely the ratio of vagally-mediated heart rate variability (vmHRV) and CRP, was proposed to index the functionality of the cholinergic anti-inflammatory pathway. This study aims to transfer and extend the previous findings to two general population-based samples to explore the hypothesis that NIM-ratio is associated with all-cause mortality. Two large population studies (MIDUS 2: N = 1255 and Whitehall II wave 5: N = 7870) with complete data from a total of N = 3860 participants (36.1% females; average age = 56.3 years; 11.1% deaths, last exit 18.1 years post inclusion) were available. NIM indices were calculated using the vagally-mediated HRV measure RMSSD divided by measures of CRP (NIMCRP) or IL-6 (NIMIL6). The NIM-ratios were quartiled and entered into age, ethnicity and body mass index adjusted Cox proportional hazards models. For NIMIL6 the lowest quartile was 45% more likely to die during the observed period (max. 18 years follow-up) compared to the highest quartile (HR = 0.55 CI 0.41–0.73; p < .0001). NIMCRP parallel these results. Here we show that an easily computable index of IL-6 inhibition is associated with all-cause mortality in two large general population samples. These results suggest that this index might be useful for risk stratification and warrant further examination.
No takes yet. Share an insight, caveat, or question.
Jarczok et al. (2021) conducted a cohort in General population (n=3,860). Highest quartile of NIM-IL6 index vs. Lowest quartile of NIM-IL6 index was evaluated on All-cause mortality (HR 0.55, 95% CI 0.41-0.73, p=<0.0001). The highest quartile of the NIM-IL6 index was associated with a 45% lower risk of all-cause mortality compared to the lowest quartile (HR 0.55).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: